
News|Articles|May 1, 2002
Methylphenidate-MAOI contraindication.
New contraindications and precautions have been added to the labeling of methylphenidate HCl tablets (Ritalin and Ritalin-SR, Novartis)-approved for treatment of attention deficit/hyperactivity disorder (ADHD).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The FDA proposes ditching comparative efficacy studies for biosimilars
2
UC Davis develops new drug for bladder cancer patients
3
Misdiagnosis of Type 1 diabetes remains a major problem, despite advances
4
Atopic dermatitis care advances in 2025 with new biologics, topicals and oral therapies
5



















































